Acute adriamycin-induced cardiotoxicity is exacerbated by angiotension II

Area of Science:

• Cardiology
• Pharmacology
• Mitochondrial Biology

Background:

• Adriamycin (ADR) is a chemotherapy drug known to induce cardiotoxicity.
• ADR increases reactive oxygen species (ROS) production, leading to mitochondrial dysfunction.
• Angiotensin II also stimulates mitochondrial ROS generation, potentially exacerbating ADR-induced damage.

Purpose of the Study:

• To investigate the protective effects of angiotensin converting enzyme (ACE) inhibitors and renin inhibitors against ADR-induced mitochondrial impairment.
• To evaluate the impact of captopril and aliskiren on cardiac function and mitochondrial health in the context of ADR treatment.

Main Methods:

• Rats were treated with ADR alone or in combination with captopril, aliskiren, or both.
• Left ventricular function and blood pressure were assessed.
• Mitochondrial membrane potential (MMP) and ATP levels were measured to evaluate mitochondrial function and oxidative stress.

Main Results:

• ADR treatment impaired left ventricular function and decreased MMP and ATP levels, indicating mitochondrial damage and increased oxidative stress.
• Co-treatment with ACE inhibitors (captopril) or renin inhibitors (aliskiren) attenuated the ADR-induced decrease in MMP and ATP levels.
• Inhibition of Angiotensin II production ameliorated the pathological changes in electrocardiogram, blood pressure, and left ventricular function.

Conclusions:

• Inhibitors of Angiotensin II, including ACE and renin inhibitors, are effective in preventing ADR-induced cardiotoxicity.
• These protective effects are mediated by the restoration of mitochondrial membrane potential and ATP production, as well as the prevention of mitochondrial damage.
• Targeting the renin-angiotensin system offers a promising therapeutic strategy against ADR cardiotoxicity.